Fildes J E, Shaw S M, Mitsidou A, Rogacev K, Leonard C T, Williams S G, Yonan N
The Transplant Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester, M23 9LT, UK.
Transpl Immunol. 2008 May;19(2):152-7. doi: 10.1016/j.trim.2008.02.002. Epub 2008 Mar 31.
Monocytes mediate immune responses following solid organ transplantation via cytokine secretion and differentiation to macrophage/dendritic cell lineages. To date, the pleiotropic immunomodulatory effect of statins on human monocytes following human heart transplantation has yet to be elucidated. This study was designed to assess the effects of statin administration on the monocyte repertoire.
108 patients were recruited into the study. Clinical data were collected from patients' notes. Peripheral blood immunophenotype was determined via flow cytometry (using CD11c, CD14, CD16, CD49d, CD64, CD80 and CD195).
There were fewer circulating classical (p=0.0001) and non-classical (p=0.0013) monocytes in patients treated with a statin. CD64 expression was down-regulated (p=0.011 and p=0.049) whereas CD49d expression was up-regulated (p=0.004 and p=0.022) on classical and non-classical monocytes in this group. Patients receiving Atorvastatin had fewer circulating classical monocytes (p=0.001) compared to patients administered Pravastatin. Patients receiving Pravastatin had fewer circulating non-classical monocytes (p=0.029) compared to patients administered Atorvastatin.
Statin administration alters the circulating monocyte repertoire following heart transplantation, including population size, FcgammaRI and VLA-4 adhesion molecule expression. Furthermore, different statin treatments are associated with a selective depletion of macrophage or DC (re)generating monocytes.
单核细胞通过分泌细胞因子以及分化为巨噬细胞/树突状细胞谱系来介导实体器官移植后的免疫反应。迄今为止,他汀类药物对人类心脏移植后人类单核细胞的多效免疫调节作用尚未阐明。本研究旨在评估他汀类药物给药对单核细胞库的影响。
108名患者被纳入该研究。从患者病历中收集临床数据。通过流式细胞术(使用CD11c、CD14、CD16、CD49d、CD64、CD80和CD195)测定外周血免疫表型。
接受他汀类药物治疗的患者中循环中的经典单核细胞(p=0.0001)和非经典单核细胞(p=0.0013)较少。在该组的经典和非经典单核细胞上,CD64表达下调(p=0.011和p=0.049),而CD49d表达上调(p=0.004和p=0.022)。与接受普伐他汀治疗的患者相比,接受阿托伐他汀治疗的患者循环中的经典单核细胞较少(p=0.001)。与接受阿托伐他汀治疗的患者相比,接受普伐他汀治疗的患者循环中的非经典单核细胞较少(p=0.029)。
他汀类药物给药改变了心脏移植后的循环单核细胞库,包括细胞数量、FcγRI和VLA-4黏附分子表达。此外,不同的他汀类药物治疗与巨噬细胞或树突状细胞(再)生成单核细胞的选择性消耗有关。